Cargando…

Preoperative plasma D-dimer independently predicts survival in patients with pancreatic ductal adenocarcinoma undergoing radical resection

BACKGROUND: Elevated plasma D-dimer levels have been reported as an unfavorable prognostic indicator in many solid tumors. However, there are limited relevant studies in pancreatic cancer patients following radical surgery, and the clinical significance remains controversial. The aim of this study w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Haoda, Li, Fanlu, Zou, Siyi, Xie, Junjie, Zhang, Jun, Deng, Xiaxing, Chen, Hao, Shen, Baiyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8191214/ https://www.ncbi.nlm.nih.gov/pubmed/34107980 http://dx.doi.org/10.1186/s12957-021-02281-8

Ejemplares similares

Postoperative hyperprogression disease of pancreatic ductal adenocarcinoma after curative resection: a retrospective cohort study
por: Zou, Siyi, et al.
Publicado: (2022)

Real‐world implications of nonbiological factors with staging, clinical management, and prognostic prediction in pancreatic ductal adenocarcinoma
por: Wang, Chao, et al.
Publicado: (2022)

Risk factors for and prognostic values of postoperative acute kidney injury after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: A retrospective, propensity score‐matched cohort study of 1312 patients
por: Ji, Yuchen, et al.
Publicado: (2022)

Long-term outcomes of standard versus extended lymphadenectomy in pancreatoduodenectomy for pancreatic ductal adenocarcinoma: A Chinese multi-center prospective randomized controlled trial
por: WANG, Weishen, et al.
Publicado: (2022)

Accuracy of Nodal Positivity in Inadequate Lymphadenectomy in Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Population Study Using the US SEER Database
por: Wang, Weishen, et al.
Publicado: (2019)

Combination of preoperative fibrinogen and D-dimer as a prognostic indicator in pancreatic ductal adenocarcinoma patients undergoing R0 resection
por: Zhang, Li-Peng, et al.
Publicado: (2021)

Health‐related quality of life and survival outcomes for patients with major depressive disorder and anxiety: A longitudinal study in pancreatic ductal adenocarcinoma
por: Ji, Yuchen, et al.
Publicado: (2023)

Preoperative recurrence prediction in pancreatic ductal adenocarcinoma after radical resection using radiomics of diagnostic computed tomography
por: Li, Xiawei, et al.
Publicado: (2021)

Tumor copy number instability is a significant predictor for late recurrence after radical surgery of pancreatic ductal adenocarcinoma
por: Wen, Chenlei, et al.
Publicado: (2020)

A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer
por: Jin, Yangbing, et al.
Publicado: (2021)

The Prognostic Index Independently Predicts Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Resection
por: Gruber, Elisabeth S., et al.
Publicado: (2020)

The Necessity of Dissection of No. 14 Lymph Nodes to Patients With Pancreatic Ductal Adenocarcinoma Based on the Embryonic Development of the Head of the Pancreas
por: Qian, Lihan, et al.
Publicado: (2020)

Higher body mass index indicated better overall survival in pancreatic ductal adenocarcinoma patients: a real-world study of 2010 patients
por: Fu, Ningzhen, et al.
Publicado: (2021)

Specific human leukocyte antigen class I genotypes predict prognosis in resected pancreatic adenocarcinoma: a retrospective cohort study
por: Wen, Chenlei, et al.
Publicado: (2023)

Prognostic value of the preoperative fibrinogen-to-albumin ratio in pancreatic ductal adenocarcinoma patients undergoing R0 resection
por: Zhang, Li-Peng, et al.
Publicado: (2020)

LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma
por: Liu, Yihao, et al.
Publicado: (2022)

The CTCF/LncRNA‐PACERR complex recruits E1A binding protein p300 to induce pro‐tumour macrophages in pancreatic ductal adenocarcinoma via directly regulating PTGS2 expression
por: Liu, Yihao, et al.
Publicado: (2022)

Preoperative Alkaline Phosphatase-to-Cholesterol Ratio as a Predictor of Overall Survival in Pancreatic Ductal Adenocarcinoma Patients Undergoing Radical Pancreaticoduodenectomy
por: Qiu, Guotong, et al.
Publicado: (2021)

Oncological outcomes of robotic-assisted versus open pancreatoduodenectomy for pancreatic ductal adenocarcinoma: a propensity score-matched analysis
por: Weng, Yuanchi, et al.
Publicado: (2020)

Who could complete and benefit from the adjuvant chemotherapy regarding pancreatic ductal adenocarcinoma? A multivariate‐adjusted analysis at the pre‐adjuvant chemotherapy timing
por: Fu, Ningzhen, et al.
Publicado: (2022)

Melittin-induced long non-coding RNA NONHSAT105177 inhibits proliferation and migration of pancreatic ductal adenocarcinoma
por: Wang, Xinjing, et al.
Publicado: (2018)

H2AK119Ub1 and H3K27Me3 in molecular staging for survival prediction of patients with pancreatic ductal adenocarcinoma
por: Chen, Shi, et al.
Publicado: (2014)

TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma
por: Zhou, Yiran, et al.
Publicado: (2023)

Risk Factors of Early Liver Metastasis for Pancreatic Ductal Adenocarcinoma after Radical Resection
por: Tong, Jingshu, et al.
Publicado: (2022)

Preoperative Serum CA125 Levels Predict the Prognosis in Hyperbilirubinemia Patients With Resectable Pancreatic Ductal Adenocarcinoma
por: Chen, Tao, et al.
Publicado: (2015)

Does Pre-operative Biliary Drainage Influence Long-Term Survival in Patients With Obstructive Jaundice With Resectable Pancreatic Head Cancer?
por: Shen, Ziyun, et al.
Publicado: (2020)

Prognostic Analysis and Influencing Serum Biomarkers of Patients With Resectable Pancreatic Adenosquamous Cancer
por: Shi, Yusheng, et al.
Publicado: (2021)

The prognostic relevance of primary tumor location in patients undergoing resection for pancreatic ductal adenocarcinoma
por: Ling, Qi, et al.
Publicado: (2017)

Sarcopenia and sarcopenic obesity are independent adverse prognostic factors in resectable pancreatic ductal adenocarcinoma
por: Gruber, Elisabeth S., et al.
Publicado: (2019)

Targeting KRAS(G12V) mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors
por: Ai, Qi, et al.
Publicado: (2023)

Efficacy and safety of laparoscopic radical resection following neoadjuvant therapy for pancreatic ductal adenocarcinoma: A retrospective study
por: He, Yong-Gang, et al.
Publicado: (2022)

Identification of copy number variation-driven molecular subtypes informative for prognosis and treatment in pancreatic adenocarcinoma of a Chinese cohort
por: Zhan, Qian, et al.
Publicado: (2021)

Comparison and validation of the value of preoperative inflammation marker-based prognostic scores in resectable pancreatic ductal adenocarcinoma
por: Ye, Sisi, et al.
Publicado: (2018)

Resectable pancreatic ductal adenocarcinoma: association between preoperative CT texture features and metastatic nodal involvement
por: Fang, Wei Huan, et al.
Publicado: (2020)

A Simple Model Established by Blood Markers Predicting Overall Survival After Radical Resection of Pancreatic Ductal Adenocarcinoma
por: Zhang, Li-xiang, et al.
Publicado: (2020)

A Novel Nomogram to Predict Survival in Patients With Recurrence of Pancreatic Ductal Adenocarcinoma After Radical Resection
por: He, Chaobin, et al.
Publicado: (2020)

A Quantitative Clinicopathological Signature for Predicting Recurrence Risk of Pancreatic Ductal Adenocarcinoma After Radical Resection
por: He, Chaobin, et al.
Publicado: (2019)

Development and validation of a nomogram to predict liver metastasis for pancreatic ductal adenocarcinoma after radical resection
por: Tong, Jingshu, et al.
Publicado: (2022)

Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan
por: Ei, Shigenori, et al.
Publicado: (2023)

Correction: Sarcopenia and sarcopenic obesity are independent adverse prognostic factors in resectable pancreatic ductal adenocarcinoma
por: Gruber, Elisabeth S., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1t0lcejk0h4n10d76qh8h006g7